RudaCure is a clinical stage 生物制药 初创企业 founded in 2018 and based in 韩国 that is developing medicines for incurable diseases based on the most advanced life-science technologies to help improve human lives. By developing treatment techniques for intractable and incurable diseases, RudaCure will solve its 未满足的需求 and treat the physical and mental pain for patients suffering from them. With creative 制药 development and biomedical research, RudaCure is on the path to grow into a global 制药公司.
Current main products in development include RCI001 for 干眼症, which is in pre-IND phase and awaiting to start Phase 2 FDA 临床试验 next year. RudaCure also plan to secure additional indications for RCI001 including conjunctivitis, keratitis and 角膜溃疡s. Second in development is RCI002, which is a non-opioid treatment for neuropathic and 慢性疼痛 currently in optimization stage. Other early stage products in development include treatments for 特应性皮炎, metastasis and CRPS.
Since April of 2021, RudaCure has successfully licensed-out RCI001 to 翰林制药 for domestic rights in a $12 million deal, and is currently looking for more investors and partners to 对外许可 for international markets. Helping RudaCure along the way, are 初创企业 accelerators MassChallenge and 新韩Square Bridge, which are both helping RudaCure enter 美国 market.